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Significance	 statement:	STAT3	is	able	to	mediate	epigenetic	silencing	of	tumor	suppressor	genes	(TSG).	However,	little	is	known	about	the	molecular	mechanisms	involved,	except	that	this	action	is	mediated	by	DNA	methylation	and	requires	STAT3	acetylation.	Here,	Gambi	and	collaborators	confirm	that	oncogene-driven	constitutive	STAT3	acetylation	is	responsible	for	TSG	 silencing.	 Further,	 they	 identify	 the	 Sin3a	 transcriptional	 repressor	 complex	 as	 an	obligatory	partner	 of	 STAT3	on	 the	promoters	 of	 the	 repressed	 genes,	 shading	 light	 on	 the	mechanisms	 involved	 in	 STAT3-mediated	 transcriptional	 repression.	 Importantly,	 this	STAT3-Sin3a	axis	emerges	as	a	potential	selective	therapeutic	target	to	specifically	hit	STAT3-dependent	tumors.			 	
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Signal	 Transducer	 and	 Activator	 of	 Transcription	 (STAT)	 3	 plays	 a	 multitude	 of	different	functions	downstream	of	cytokines	and	growth	factors	receptors	and	of	oncogenes.	Failure	 of	 tightly	 controlling	 its	 activation,	 leading	 to	 aberrant	 constitutive	 activity,	 is	 a	hallmark	 of	 pathological	 conditions	 including	 inflammatory	 and	 auto-immune	 diseases	 and	cancer	 (1),	 and	 indeed	 addiction	 to	 STAT3	 activity	 is	 a	 frequent	 feature	 of	 many	 different	tumors.	 Despite	 the	 general	 agreement	 on	 STAT3	 being	 an	 oncogene,	 its	 specific	 role	 in	tumors	is	far	from	straightforward.	Indeed,	while	in	most	cases	STAT3	activities	contribute	in	multiple	ways	to	tumor	transformation,	growth	and	progression,	this	factor	can	also	act	as	a	tumor	 suppressor,	 inducing	 apoptosis	 or	 reducing	 motility	 and	 Epithelial	 to	 Mesenchymal	Transition	(1),	supporting	the	 idea	that	STAT3	activities	and	functions	are	strongly	context-	and	 cell	 type-specific.	 Likewise,	 while	 the	 best	 characterized	 nuclear	 activities	 of	 STAT3	relevant	 to	 cancer	 are	 related	 to	 transcriptional	 induction,	 it	 has	 often	 been	 observed	 that	more	genes	are	up-regulated	rather	than	down-regulated	as	a	consequence	of	its	inactivation	in	 cancer	 cells,	 suggesting	 that	 the	 ability	 to	 repress	 transcription	 of	 specific	 target	 genes	plays	 a	 relevant	 role	 in	 STAT3	pro-oncogenic	 activities.	 Indeed,	 constitutively	 active	 STAT3	was	shown	to	be	essential	to	trigger	and	maintain	the	silencing	of	several	tumor	suppressor	genes	(TSGs)	in	NPM-ALK-+	T	cell	anaplastic	large	cells	lymphomas	(ALCL),	breast	cancer	and	melanoma	(2,	3).		 The	multiple	and	sometimes	contradictory	roles	played	by	STAT3	are	likely	the	result	of	a	number	of	factors,	not	least	the	numerous	post-translational	modifications	that	regulate	both	 its	 canonical	 nuclear	 activities	 and	 its	 non-canonical	 functions	 in	 the	 cytoplasm,	 the	mitochondria	and	the	Endoplasmic	Reticulum	(4).	While	phosphorylation	on	Tyrosine	705	(Y-P)	is	required	for	STAT3	dimerization,	nuclear	localization,	DNA	binding	and	transcriptional	activities,	Serine-727	phosphorylation	(S-P)	enhances	STAT3	trans-activating	ability	but	more	importantly	is	required	for	its	non-canonical	functions	in	both	the	mitochondria	and	the	ER,	modulating	OXPHOS	activities,	ER	Calcium	signaling	and	apoptotic	responses	(5,	6).	As	to	the	other	 PTMs,	 Lysine	methylation	 and	 Cysteine	 oxidation	 or	 glutathionylation	 reduce	 STAT3	trans-activating	power,	while	acetylation,	which	has	been	observed	on	Lysine	residues	within	both	 the	 N-terminal	 and	 the	 TAD	 domains	 mainly	 downstream	 of	 the	 CBP/p300	 Histone	Acetyl	 Transferase	 (4),	 is	 associated	 to	 enhanced	 transcriptional	 activity	 because	 of	 dimer	stabilization	 and	 enhanced	 Tyr-phosphorylation,	 nuclear	 localization	 and	 interaction	 with	CBP/p300.		
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	 Indeed,	 like	 all	 other	 STATs,	 STAT3	 trans-activating	 potential	 mainly	 relies	 on	 the	ability	of	recruiting	to	promoters	the	Histone	Acetyl	Transferase	(HAT)	CBP/p300,	triggering	localized	 histone	 hyperacetylation.	 On	 the	 other	 hand,	 STAT3-mediated	 transcriptional	repression	of	TSGs	was	shown	to	require	its	acetylation	on	the	K867	residue	and	to	correlate	with	 DNMT1	 interaction	 and	 promoter	 hypermethylation	 (3).	 However,	 why	would	 STAT3	complex	 with	 DNMT1	 on	 the	 regulatory	 regions	 of	 tumor	 suppressor	 genes	 and	 trigger	epigenetic	 silencing,	while	 recruiting	 CBP/p300	 leading	 to	 activation	 of	 cell-cycle	 and	 anti-apoptotic	genes	promoters,	is	so	far	still	a	mystery.		The	 findings	 described	 by	 Gambi	 and	 colleagues	 in	 this	 issue	 of	 Cancer	 Research	partially	shed	light	on	the	mechanisms	involved	(7).	A	conundrum	in	type	I	IFN	signaling	was	its	well-known	ability	to	trigger	anti-viral	and	antiproliferative	responses	via	the	activation	of	the	 ISGF3	 transcriptional	 complex	 (STAT1:	 STAT2:IRF9)	 while	 failing	 to	 induce	 STAT3-mediated	 transcription	 despite	 its	 canonical	 robust	 activation.	 These	 data	 suggested	 the	ability	 to	 uncouple	 the	 phosphorylation	 and	DNA	 binding	 activity	 of	 STAT3	 from	 its	 trans-activating	power.	Previous	work	by	Icardi	and	co-workers	in	Jan	Tavernier’s	group	(8)	led	to	the	 identification	 of	 Sin3a,	 the	 central	 component	 of	 the	 Sin3a	 co-repressor	 complex,	 as	 a	direct	 partner	 of	 acetylated	 STAT3.	 Sin3a	 and	 STAT3	 co-localized	 at	 promoters	 of	 STAT3	target	 genes	 upon	 both	 type	 I	 IFN	 and	 LIF	 treatment,	 involved	 STAT3	 Y-P	 as	 well	 as	 K-acetylation.	Despite	the	involvement	of	the	DNA	Binding	Domain	of	STAT3,	devoid	of	known	acetylated	 residues,	 the	 interaction	was	 greatly	 enhanced	 by	 acetylation	 on	 the	N-terminal	K87	 residue,	 and	 promoted	 STAT3	 deacetylation	 and	 segregation	 from	 the	 nucleus.	Importantly,	 these	 effects	 were	 tightly	 cell-specific,	 as	 Sin3a	 did	 not	 affect	 LIF	 or	 IL-6-mediated	 induction	 of	 acute	 phase	 response	 genes	 in	 hepatoma	 cells.	 This	work	 identified	Sin3a	as	an	 important	regulator	of	STAT3	transcriptional	activity,	able	both	of	 inhibiting	 its	trans-activating	 potential	 downstream	of	 type	 I	 IFN,	 curbing	 its	 pro-proliferative	 functions,	and	of	modulating	the	amplitude	of	STAT3-mediated	transcriptional	induction	downstream	of	its	canonical	stimuli	such	as	LIF	or	IL-6.	In	the	present	issue,	Gambi	and	colleagues	show	that	Sin3a	is	also	the	main	mediator	of	the	epigenetic	silencing	of	TSGs	triggered	by	STAT3	in	both	ALCL	 and	 triple	 negative	 breast	 cancer	 (7).	 Indeed,	 oncogene-induced	 constitutively	acetylated	 STAT3	 and	 Sin3a	 bind	 as	 a	 complex	 to	 TSG	 promoters,	 and	 inhibition	 of	 STAT3	acetylation	(and	S-P)	by	resveratrol	decreases	this	binding	while	reactivating	the	expression	of	 a	 number	 of	 TSGs	 in	 ALCL.	 On	 the	 other	 hand,	 also	 Sin3a	 silencing	 increases	 TSGs	expression,	 impairing	 cell	 growth	 both	 in	 vitro	 and	 in	 vivo	 and	 enhancing	 spontaneous	
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apoptosis.	 These	 findings	 bridge	 the	 previously	 reported	 ability	 of	 type	 I	 IFN	 to	 repress	STAT3-mediated	 transcription	 (8)	 with	 the	 ability	 of	 constitutively	 acetylated	 STAT3	 to	trigger	the	epigenetic	repression	of	TSGs	(3).	Both	activities	indeed	require	Sin3a	and	Sin3a-STAT3	 interactions	 at	 gene	 promoters.	 Sin3a	 prominent	 role	 in	 STAT3-dependent	transcriptional	repression	is	compatible	with	the	reported	DNA	methylation	on	the	repressed	gene	promoters,	and	with	the	recruitment	of	DNMT1,	HDAC1	and	MeCP2,	which	are	all	known	interactors	of	the	Sin3a	co-repressor	complex.		Several	 questions	 remain	 still	 open.	 In	 particular,	 the	 exact	 interplay	 of	 signaling	events	regulating	STAT3	acetylation	levels	is	poorly	understood,	along	with	the	identification	of	the	Lysine	residues	implicated.	Indeed,	in	the	present	paper	the	authors	show	that	STAT3	K685	acetylation	levels	correlate	with	STAT3-mediated	TSGs	repression	and	Sin3a	interaction.	However,	 other	 Lysine	 residues	 are	 likely	 involved,	 since	 either	 acetyl-deficient	 or	 acetyl-mimicking	mutations	of	K685	failed	to	affect	Sin3a	binding.	One	candidate	is	the	K87	residue	within	 the	N-terminal	 domain,	which	was	 shown	 to	 enhance	 STAT3-Sin3a	 interactions	 (8).	However,	there	are	about	47	conserved	Lysines	in	the	STAT3	sequence.	These	will	have	to	be	characterized	 to	 assess	 their	 acetylation	 and	 how	 it	 is	 regulated	 downstream	 of	 different	signals	in	order	to	shed	complete	light	on	the	pathway.	Although	the	mechanism	of	action	of	resveratrol,	which	reduces	both	S-P	and	K-acetylation	on	STAT3,	 is	poorly	understood,	MAP	kinases,	 PI3K	 and	 mTOR,	 all	 activated	 downstream	 of	 NPM-ALK,	 have	 been	 variably	implicated	 in	 STAT3	 S-P	 and	 K-A.	 In	 particular	 mTOR,	 a	 known	 resveratrol	 target,	 could	represent	the	key	molecule	involved	in	coordinately	orchestrating	STAT3	S-P	and	K-A	levels.	Likewise,	 unknown	 are	 the	molecular	 events	 determining	whether	 the	 STAT3-Sin3a	complex	bound	to	genes’	regulatory	regions	 leads	to	 i)	moderated	transcriptional	activation	upon	stimulation	with	the	canonical	physiological	STAT3	activators	IL-6	and	LIF,	ii)	impaired	trans-activating	 power	 following	 type	 I	 IFNs	 treatment,	 or	 iii)	 active	 transcriptional	repression	 downstream	 of	 oncogenic	 activation.	 Each	 of	 the	 named	 stimuli	 can	 activate	distinct	 signaling	 pathways,	 likely	 leading	 to	 even	 subtly	 different	 PTM	 combinations	 on	STAT3	and	 to	 the	 concomitant	activation	of	 alternative	 transcription	 factors	and	co-factors,	which	 in	 turn	 can	 determine	 the	 final	 transcriptional	 output.	 In	 this	 vein	 both	 STAT1	 and	STAT3,	which	exhibit	opposite	 functions,	have	been	 shown	 to	 cross-regulate	 their	 activities	downstream	of	 type	 II	 IFNs	 and	 IL-6,	 respectively,	 contributing	 to	 shape	 cytokine	 signaling	specificity	and	suggesting	that	the	abundance	and	activation	status	of	these	two	factors	may	significantly	 qualitatively	 and	 quantitatively	 alter	 cytokine	 responses	 (9,	 10).	 Indeed,	 the	
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ability	of	either	factor	to	compensate	for	each	other’s	absence	suggests	that	the	cellular	and	signaling	 context	 leading	 to	 their	 activation	 determines	 whether	 genes	 are	 activated,	 not	activated	 or	 even	 repressed.	 It	 is	 tempting	 to	 speculate	 that	 these	 effects	 could	 be	 at	 least	partially	mediated	 by	 STAT3	 acetylation	 patterns	 and	 the	 degree	 of	 interaction	with	 Sin3a	downstream	of	different	signals.	In	 conclusion,	 the	 schematic	 dogma	 establishing	 that	 there	 are	 two	 forms	 of	 STAT3,	either	 unphosphorylated	 and	 inactive	 or	 phosphorylated	 and	 active,	 has	 since	 long	 been	disproven.	 STAT3	 comes	 in	 many	 flavors,	 which	 modulate	 its	 functions	 in	 different	 cell	compartments.	Even	only	concentrating	on	its	nuclear	functions,	the	specific	distribution	of	its	many	PTMs	can	subtly	regulate	specific	functions	determining	the	subsets	of	genes	that	are	in	each	 case	 activated,	 not	 activated	 or	 repressed.	 Considering	 the	 many	 physiological	 and	pathological	 functions	 of	 STAT3,	 one	may	 predict	 that	 a	 generalized,	 good-for-all	 inhibitor,	which	many	laboratories	and	pharmaceutical	companies	are	striving	to	develop,	may	reveal	toxic	 and/or	 not	 sufficiently	 specific.	 Understanding	 the	 molecular	 bases	 regulating	 the	multifaceted	 functions	 of	 STAT3	 and	 its	 PTMs	may	 offer	 opportunities	 to	 try	 and	 develop	inhibitors	 of	 specific	 functions,	 either	 in	 the	 cytoplasm	 or	 in	 the	 nucleus.	 Accordingly,	 the	work	 here	 described	 suggests	 that	 decoy	 molecules	 able	 to	 disrupt	 the	 Sin3a-STAT3	interaction	could	allow	to	specifically	reactivate	TSGs	in	those	tumors	that	exhibit	addiction	to	STAT3	activity.	
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